|
Gene: SH2D4A |
Gene summary for SH2D4A |
Gene summary. |
Gene information | Species | Human | Gene symbol | SH2D4A | Gene ID | 63898 |
Gene name | SH2 domain containing 4A | |
Gene Alias | PPP1R38 | |
Cytomap | 8p21.3 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q9H788 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
63898 | SH2D4A | LZE4T | Human | Esophagus | ESCC | 9.63e-05 | 2.19e-01 | 0.0811 |
63898 | SH2D4A | LZE5T | Human | Esophagus | ESCC | 8.35e-04 | 2.48e-01 | 0.0514 |
63898 | SH2D4A | LZE8T | Human | Esophagus | ESCC | 3.14e-03 | 1.46e-01 | 0.067 |
63898 | SH2D4A | LZE20T | Human | Esophagus | ESCC | 6.18e-05 | 1.76e-01 | 0.0662 |
63898 | SH2D4A | LZE24T | Human | Esophagus | ESCC | 7.96e-10 | 3.83e-01 | 0.0596 |
63898 | SH2D4A | P1T-E | Human | Esophagus | ESCC | 1.05e-21 | 9.79e-01 | 0.0875 |
63898 | SH2D4A | P2T-E | Human | Esophagus | ESCC | 3.27e-09 | 2.48e-01 | 0.1177 |
63898 | SH2D4A | P4T-E | Human | Esophagus | ESCC | 6.48e-14 | 4.00e-01 | 0.1323 |
63898 | SH2D4A | P5T-E | Human | Esophagus | ESCC | 3.99e-07 | 1.36e-01 | 0.1327 |
63898 | SH2D4A | P8T-E | Human | Esophagus | ESCC | 1.64e-19 | 3.91e-01 | 0.0889 |
63898 | SH2D4A | P9T-E | Human | Esophagus | ESCC | 7.84e-10 | 2.14e-01 | 0.1131 |
63898 | SH2D4A | P10T-E | Human | Esophagus | ESCC | 1.68e-08 | 2.14e-01 | 0.116 |
63898 | SH2D4A | P12T-E | Human | Esophagus | ESCC | 3.17e-05 | 6.69e-02 | 0.1122 |
63898 | SH2D4A | P17T-E | Human | Esophagus | ESCC | 3.45e-04 | 2.67e-01 | 0.1278 |
63898 | SH2D4A | P20T-E | Human | Esophagus | ESCC | 1.74e-13 | 3.20e-01 | 0.1124 |
63898 | SH2D4A | P21T-E | Human | Esophagus | ESCC | 6.84e-04 | 1.56e-01 | 0.1617 |
63898 | SH2D4A | P22T-E | Human | Esophagus | ESCC | 1.32e-07 | 1.04e-01 | 0.1236 |
63898 | SH2D4A | P23T-E | Human | Esophagus | ESCC | 7.98e-19 | 5.61e-01 | 0.108 |
63898 | SH2D4A | P24T-E | Human | Esophagus | ESCC | 7.00e-11 | 3.09e-01 | 0.1287 |
63898 | SH2D4A | P26T-E | Human | Esophagus | ESCC | 1.99e-14 | 3.26e-01 | 0.1276 |
Page: 1 2 3 4 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SH2D4A | SNV | Missense_Mutation | rs778282714 | c.308G>A | p.Arg103Gln | p.R103Q | Q9H788 | protein_coding | tolerated(0.44) | benign(0.005) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SH2D4A | SNV | Missense_Mutation | novel | c.1220N>A | p.Gly407Asp | p.G407D | Q9H788 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
SH2D4A | SNV | Missense_Mutation | novel | c.898T>C | p.Tyr300His | p.Y300H | Q9H788 | protein_coding | tolerated(0.54) | benign(0) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
SH2D4A | SNV | Missense_Mutation | c.1189N>A | p.Asp397Asn | p.D397N | Q9H788 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SH2D4A | SNV | Missense_Mutation | novel | c.344N>C | p.Lys115Thr | p.K115T | Q9H788 | protein_coding | tolerated(0.05) | benign(0.03) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SH2D4A | SNV | Missense_Mutation | novel | c.1065N>T | p.Lys355Asn | p.K355N | Q9H788 | protein_coding | tolerated(0.1) | benign(0.037) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
SH2D4A | SNV | Missense_Mutation | novel | c.232N>A | p.Val78Ile | p.V78I | Q9H788 | protein_coding | deleterious(0.03) | benign(0.123) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SH2D4A | SNV | Missense_Mutation | novel | c.319G>A | p.Glu107Lys | p.E107K | Q9H788 | protein_coding | tolerated(0.25) | benign(0) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
SH2D4A | SNV | Missense_Mutation | novel | c.1207N>C | p.Tyr403His | p.Y403H | Q9H788 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-FI-A2EU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatinum | CR |
SH2D4A | insertion | Frame_Shift_Ins | novel | c.618dupA | p.Gln207ThrfsTer3 | p.Q207Tfs*3 | Q9H788 | protein_coding | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |